𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Survival in multiple system atrophy

✍ Scribed by Anette Schrag; Gregor K. Wenning; Niall Quinn; Yoav Ben-Shlomo

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
80 KB
Volume
23
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

We here report survival in patients with multiple system atrophy (MSA) in a large, prospectively studied group of patients with MSA. Eighty‐five of 100 patients were known to have died. Three patients were rediagnosed as having PD. Twenty‐four patients came to autopsy, which showed MSA in 22 and idiopathic Parkinson's disease in 2. The median survival time was 8.6 and 7.3 years for men and women, respectively (hazard ratio for women was 1.49, 95% CI 0.97–2.31, P = 0.07). Except for rediagnosis as PD, no predictive factors for better survival could be identified. These data confirm the relatively poor prognosis of MSA of less than 9 years on average. Β© 2007 Movement Disorder Society

πŸ“œ SIMILAR VOLUMES

Therapeutic strategies in multiple syste
Therapeutic strategies in multiple system atrophy
✍ Gregor K. Wenning; Felix Geser; Werner Poewe πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 92 KB

This review provides an update on therapeutic principles and their implications for practical management in multiple system atrophy (MSA), a sporadic neurodegenerative disorder characterized clinically by various combinations of dysautonomia, Parkinsonism, or cerebellar ataxia, often associated with

Facial myokymia in multiple system atrop
Facial myokymia in multiple system atrophy
✍ Dr. S. B. Blunt; N. M. Khalil; G. D. Perkin πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 400 KB

## Abstract Two patients are described with clinical and neuroimaging features consistent with a diagnosis of multiple system atrophy (MSA). The patients are unusual in that facial myokymia became apparent clinically at some stage in their illness. In each patient, the nature and severity of the in

Multiple system atrophy: An update
Multiple system atrophy: An update
✍ Gregor K. Wenning; Felix Geser; Michaela Stampfer-Kountchev; FranΓ§ois Tison πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 90 KB

Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder that usually manifests in the early sixth decade of life and progresses relentlessly with a mean survival of 9 years. Clinically, MSA is dominated by autonomic/urogenital failure, which may be associated with either levodopa (L-d

Stridor and death in multiple system atr
Stridor and death in multiple system atrophy
✍ Michael H. Silber; Samantha Levine πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 47 KB πŸ‘ 2 views

Patients with multiple system atrophy (MSA) have a mean survival of 8 to 10 years. Nocturnal stridor has been considered a poor prognostic feature. We analyzed demographic, clinical, and polysomnographic data and obtained follow-up information from 42 patients with MSA (30 with follow-up data) seen